Subcutaneous delivery increases accessibility and introduces potential for at-home

administration, following model of diabetes and GLP-1 drugs

NEW YORK , Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for weekly maintenance dosing following the 18-month IV initiation phase. This is a major advancement that opens the door for faster and simpler drug delivery and paves the way for combination therapies – the same strategy that revolutionized cancer care.

"This shift to subcutaneous maintenance dosing is a crucial step toward making Leqembi more accessible for patients, similar to how diabetes and GLP-1 medications are delivered, and represents the first s

See Full Page